References:
  1. Sassi A, Lazaroski S, Wu G, et al. Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. J Allergy Clin Immunol . 2014; 133(5):1410-9, 1419.e1-13.
  2. Nihal A, Comstock JR, Holland KE, Singh AM, Seroogy CM, Arkin LM. Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab. Pediatr Dermatol. 2022 Nov;39(6):940-942.
  3. Minegishi Y, Saito M, Morio T, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity .
  4. Béziat V, Li J, Lin JX, et al. A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity. Sci Immunol . 2018;3(24):eaat4956.
  5. Ma CA, Stinson JR, Zhang Y, et al. Germline hypomorphic CARD11 mutations in severe atopic disease [published correction appears in Nat Genet. 2017 Oct 27;49(11):1661]. Nat Genet . 2017;49(8):1192-1201.
  6. Shahin T, Aschenbrenner D, Cagdas D, et al. Selective loss of function variants in IL6ST  cause Hyper-IgE syndrome with distinct impairments of T-cell phenotype and function. Haematologica . 2019;104(3):609-621.
  7. Felgentreff K, Siepe M, Kotthoff S, et al. Severe eczema and Hyper-IgE in Loeys-Dietz-syndrome - contribution to new findings of immune dysregulation in connective tissue disorders. Clin Immunol . 2014;150(1):43-50.
  8. Ponsford MJ, Klocperk A, Pulvirenti F, et al. Hyper-IgE in the allergy clinic–when is it primary immunodeficiency?. Allergy . 2018;73(11):2122-2136.
  9. Stray-Pedersen A, Backe PH, Sorte HS, et al. PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia. Am J Hum Genet . 2014; 95(1):96-107.
  10. Bernth-Jensen JM, Holm M, Christiansen M. Neonatal-onset T(-)B(-)NK(+) severe combined immunodeficiency and neutropenia caused by mutated phosphoglucomutase 3. J Allergy Clin Immunol . 2016 Jan;137(1):321-324.
  11. Zhang Y, Yu X, Ichikawa M, et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol . 2014;133(5):1400-1409.e14095.
  12. Lindberg RE, Arroyave C. Levels of IgE in serum from normal children and allergic children as measured by an enzyme immunoassay. J Allergy Clin Immunol. 1986 Oct;78(4 Pt 1):614-8.
  13. Ittiwut C, Manuyakorn W, Tongkobpetch S, et al. Compound Heterozygous PGM3 Mutations in a Thai Patient with a Specific Antibody Deficiency Requiring Monthly IVIG Infusions. Journal of clinical immunology , 2020; 40(1), 227–231.
  14. Liu XR, Bian WJ, Wang J, et al. Heterozygous PGM3  Variants Are Associated With Idiopathic Focal Epilepsy With Incomplete Penetrance. Front Genet . 2020; 11:559080.
  15. Lundin KE, Hamasy A, Backe PH, et al. Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene.Clin Immunol . 2015; 161(2):366-72.
  16. Gennery AR, Flood TJ, Abinun M, et al. Bone marrow transplantation does not correct the hyper IgE syndrome. Bone Marrow Transplant . 2000;25(12):1303-1305.
  17. Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021; 35(2):464-475.
  18. Staudacher O, Krüger R, Kölsch U, et al. Relieving job: Dupilumab in autosomal dominant STAT3 hyper-IgE syndrome. J Allergy Clin Immunol Pract . 2022; 10(1):349-351.e1.
  19. Lévy R, Béziat V, Barbieux C, et al. Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome. J Clin Immunol . 2020; 40(2):418-420.
  20. Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J Am Acad Dermatol . 2021;84(1):139-147.